Recent Developments in Contrast Media

Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast agents accumulate in tissues inside patients. This has raised concern because prolonged, elevated levels of gadolinium in the body may cause a nephrogenic systemic fibrosis in patients with severe kidney disease. Adding to this concern were three studies in 2015, which raised new gadolinium safety concerns after it was found the agent also accumulates in the brain

Latest Trends in Contrast Media Injectors

GE Healthcare Issues Update on Iodinated Contrast Media

Contrast Media Imaging Technology News

Life Sciences on X: Development of contrast media for magnetic resonance imaging / X

Imaging Technology News - Magnetic Resonance Imaging (MRI)

Contrast Media Market - Trends, Size, Growth

Iodinated contrast use before, during and after COVID: Trends predict significant growth in demand

New advances in development of GE Healthcare's manganese-based MRI contrast agent

Lifecycle of Gadolinium‐Based Contrast Agents - Liu - 2021 - Journal of Magnetic Resonance Imaging - Wiley Online Library

Imaging Technology News - Contrast Media

Statement from the ACR Committee on Drugs and Contrast Media

The Debate Over Gadolinium MRI Contrast Toxicity

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

AI Software Confirms the Results of a Large Scale Comparison of Gadoteridol and Gadavist Injection